Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 27
Summary
- Conditions
- Adenocarcinoma of the Bladder
- Metastatic Bladder Cancer
- Non-Transitional Cell Carcinoma of the Urothelial Tract
- Small Cell of the Bladder
- Squamous Cell Carcinoma of the Bladder
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This is a single-arm, phase II study with a Simon minimax design testing the combination of durvalumab and tremelimumab in patients with non-TCC of the urothelial tract.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03430895
- Collaborators
- AstraZeneca
- Investigators
- Principal Investigator: Samuel Funt, MD Memorial Sloan Kettering Cancer Center
Get Well Soon